Resistance to 6-methylpurine is conferred by defective adenine phosphoribosyltransferase in Tetrahymena by Akematsu, Takahiko et al.




Resistance to 6-methylpurine is conferred by












See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Akematsu, Takahiko; Findlay, Andrew; Fukuda, Yasuhiro; Pearlman, Ronald E.; Loidl, Josef; Orias, Eduardo; and Hamilton, Eileen P.,
,"Resistance to 6-methylpurine is conferred by defective adenine phosphoribosyltransferase in Tetrahymena." Genes.9,4. 179. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/6765
Authors
Takahiko Akematsu, Andrew Findlay, Yasuhiro Fukuda, Ronald E. Pearlman, Josef Loidl, Eduardo Orias, and
Eileen P. Hamilton
This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/open_access_pubs/6765
genes
G C A T
T A C G
G C A T
Article
Resistance to 6-Methylpurine is Conferred by
Defective Adenine Phosphoribosyltransferase
in Tetrahymena
Takahiko Akematsu 1,* ID , Andrew Findlay 2,†, Yasuhiro Fukuda 3, Ronald E. Pearlman 4,
Josef Loidl 1 ID , Eduardo Orias 2 and Eileen P. Hamilton 2
1 Department of Chromosome Biology, University of Vienna, 1030 Vienna, Austria; josef.loidl@univie.ac.at
2 Department of Molecular, Cellular and Developmental Biology, University of California at Santa Barbara,
Santa Barbara, CA 93106, USA; arfindlay@wustl.edu (A.F.); eduardo.orias@lifesci.ucsb.edu (E.O.);
eileen.hamilton@lifesci.ucsb.edu (E.P.H.)
3 Department of Biodiversity Science, Division of Biological Resource Science, Graduate School of
Agricultural Science, Tohoku University, Oosaki 989-6711, Japan; yasuhiro.fukuda.b7@tohoku.ac.jp
4 Department of Biology, York University, Toronto, ON M3J 1P3, Canada; ronp@yorku.ca
* Correspondence: takahiko.akematsu@univie.ac.at; Tel.: +43-1-4277-56251
† Current address: Department of Neurology, Neuromuscular Division, Washington University School of
Medicine, St Louis, MO 63110, USA.
Received: 19 February 2018; Accepted: 20 March 2018; Published: 23 March 2018


Abstract: 6-methylpurine (6mp) is a toxic analog of adenine that inhibits RNA and protein synthesis
and interferes with adenine salvage mediated by adenine phosphoribosyltransferase (APRTase).
Mutants of the ciliated protist Tetrahymena thermophila that are resistant to 6mp were isolated in 1974,
but the mechanism of resistance has remained unknown. To investigate 6mp resistance in T. thermophila,
we created 6mp-resistant strains and identified a mutation in the APRTase genomic locus (APRT1) that
is responsible for 6mp resistance. While overexpression of the mutated APRT1 allele in 6mp-sensitive
cells did not confer resistance to 6mp, reduced wild-type APRT1 expression resulted in a significant
decrease in sensitivity to 6mp. Knocking out or reducing the expression of APRT1 by RNA interference
(RNAi) did not affect robust cell growth, which indicates that adenine salvage is redundant or that de
novo synthesis pathways provide sufficient adenosine monophosphate for viability. We also explored
whether 6mp resistance could be used as a novel inducible selection marker by generating 6mp- and
paromomycin-resistant double mutants. While 6mp- and paromomycin-resistant double mutants did
express fluorescent proteins in an RNAi-based system, the system requires optimization before 6mp
resistance can be used as an effective inducible selection marker.
Keywords: 6-methylpurine; adenine phosphoribosyltransferase; mutation; selection marker;
Tetrahymena thermophila
1. Introduction
The ciliated protist Tetrahymena thermophila is a powerful model system that can be used to
investigate fundamental cell and molecular structures and processes [1] such as self-splicing introns [2],
small RNA-mediated genome rearrangement [3], telomeres and telomerase [4], meiosis in the absence
of a synaptonemal complex [5], and selective nuclear autophagy [6]. A greater variety of selection
markers for studying gene function and gene product localization would further enhance the utility of
T. thermophila. However, at present selection markers are limited to drug resistance markers against
paromomycin/neomycin [7,8], blasticidin [9,10], puromycin [11], and cycloheximide [12,13].
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As other ciliates, T. thermophila maintains differentiated germline and somatic nuclear genomes
in a single cytoplasm [14]. The small, essentially transcriptionally silent diploid micronucleus (MIC)
contains the germline genome, while the large, transcriptionally active polyploid macronucleus (MAC)
houses the somatic genome. The phenotype of a cell, therefore, depends on the genetic constitution of
the MAC, whereas only the genetic makeup of the MIC is inherited to progeny MICs and MACs during
sexual reproduction (illustrated in Figure 1). Unlike the MIC, in which the chromosomes are mitotically
distributed into the daughter nuclei, the MAC divides amitotically. Thus, MAC chromosomes are
randomly segregated at every cell fission [15,16].
Figure 1. Cartoon illustrating nuclear dualism and inheritance in Tetrahymena thermophila. (A) Cell with
a diploid micronucleus (MIC) and polyploid macronucleus (MAC). A cell is called a homokaryon if
MIC and MAC carry the same alleles. (B) During sexual reproduction, two cells of different mating
type pair (fuse at the anterior end). The MIC in each mate undergoes meiosis; in each mate three
meiotic products are destroyed, while the remaining product divides to form two pronuclei. Mates
exchange pronuclei, which then fuse resulting in a diploid zygotic nucleus. This nucleus divides giving
rise to the new MICs and MACs; at the same time the parental MAC are destroyed. (C) Random
assortment of MAC chromosomes over repeated amitotic divisions can result in homozygosity of the
MAC whereas the diploid MIC, which divides by mitosis, remains heterozygous. A cell with a MIC
and a MAC that have different genetic compositions is called a hetetokaryon.
Wild-type T. thermophila strains are sensitive to 6-methylpurine (6mp), a toxic adenine analog
that inhibits enzymes that bind to adenine [17,18]. Byrne et al. [19] used N-methyl-N′-nitro-N-
nitrosoguanidine (MNNG) mutagenesis to create a 6mp-resistant (6mpr) progeny cell by introducing
mutation(s) in the parental MIC (illustrated in Figure 2A). Backcrosses to a 6mp-sensitive
(MPR1-1/MPR1-1, 6mps) wild-type cells indicated that the MIC genotype was heterozygous
(mpr1-1/MPR1-1), which demonstrates that heterozygosity in the MAC is sufficient to attenuate
the toxic activity of 6mp. Random assortment of alleles in the MAC enabled the establishment of
6mps assorters, which are phenotypically sensitive to the drug but retain the heterozygous MIC
(mpr1-1/MPR1-1). Numerous rounds of single-cell isolation, followed by culturing in the absence
of 6mp, enabled assortment (Figure 2A). Bruns et al. [20] mated these heterozygous heterokaryons
(mpr1-1/MPR1-1, 6mps) to a star (*) strain (i.e., a specialized T. thermophila strain with a defective
MIC [21]) and obtained functional homozygous heterokaryons (mpr1-1/mpr1-1, 6mps) through the
first round of mating in genomic exclusion [1] (Figure 2B). These engineered strains are widely used
in laboratories to simplify genetic analysis, as they allow for direct selection of sexual progeny cells.
However, the nature of the mutation(s) induced by MNNG has not yet been characterized.
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Figure 2. Cartoon illustrating processes leading to functional homozygous heterokaryons in
T. thermophila. (A) N-methyl-N′-nitro-N-nitrosoguanidine (MNNG) mutagenesis was used to induce
mutation(s) in the parental MIC (MPR1-1/MPR1-1) of one parent strain to create a 6mp-resistant (mpr1,
6mpr) heterozygous (mpr1-1/MPR1-1) progeny cell (Byrne et al. [19]). Numerous rounds of single-cell
isolation, followed by culturing in the absence of 6mp established 6mp-sensitive (MPR1, 6mps)
assorters, which retain the heterozygous MIC (mpr1-1/MPR1-1). (B) The heterozygous heterokaryon
was mated to a star strain with a dysfunctional MIC to obtain functional homozygous heterokaryons
(mpr1-1/mpr1-1, [MPR1, 6mps]) (Bruns et al. [20]). Non-star side cells are widely used in laboratories as
pedigreed wild-type strains. Black and white nuclei indicate 6mp-resistant and -sensitive genotypes,
respectively. † denotes unselected haploid nuclei MICs (pronuclei) destined to degrade.
Two 6mpr mutant strains have been described in the red bread mold Neurospora crassa [22].
Although the nature of 6mp resistance in these strains is unknown, Pendyala et al. [22] detected
defective activity of adenine phosphoribosyltransferase (APRTase), which catalyzes phosphoribosyl
transfer from phosphoribosyl pyrophosphate (PRPP) to adenine to produce adenosine monophosphate
(AMP) [23]. Zhang et al. [24] found 6mpr strains in natural isolates of the hyperthermophilic archaeon
Sulfolobus islandicus. These strains carry mutations in the APRTase gene APRT [24]. Moreover, knocking
out the gene in a 6mps strain resulted in a 6mpr phenotype [24], strongly suggesting that impaired
APRTase activity prevents the conversion of 6mp to the nucleotide form.
In the present study, we induced mutation(s) in the APRT1 locus of T. thermophila 6mpr strains.
We also overexpressed this gene in a 6mps strain, and inactivated it by knockout and knockdown.
Our results provide the first genetic evidence in a eukaryote of a relationship between APRTase and the
6mpr phenotype. Finally, we investigated the utility of APRT1 as a new selectable drug-resistance marker.
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2. Materials and Methods
2.1. Strains, Culture Conditions, and Cell Counting
T. thermophila strains CU369 (mpr1-1/mpr1-1 [MPR1; 6mps, mating type IV]), CU428.2 (mpr1-1/mpr1-1
[MPR1; 6mps, mating type VII]), B2086.2 (MPR1-1/MPR1-1 [MPR1; 6mps, mating type II]), and A*V
(a star strain that lacks a genetically functional micronucleus, mating type V) were obtained from
the Tetrahymena Stock Center at Cornell University (USA) (https://tetrahymena.vet.cornell.edu/).
A strain (MPR1-1/MPR1-1 [MPR1; 6mps]) that expresses histone H3 with a C-terminal mCherry
fluorescent protein tag (HHT-mCherry) was a gift from Dr. Kensuke Kataoka (National Institute for
Basic Biology, Okazaki, Japan). Cells were grown at 30 ◦C in super proteose peptone (SPP) medium
containing 1% proteose peptone (Becton Dickinson, Sparks, MD, USA), 0.1% yeast extract (Becton
Dickinson), 0.2% glucose (Sigma-Aldrich, St. Louis, MO, USA), and 0.003% EDTA-Fe (Sigma-Aldrich).
6mp (Sigma-Aldrich) dissolved in distilled water at 15 mg/mL was used as a stock solution. For growth
curves, approximately 5 × 104 cells were inoculated in 1 mL of SPP containing 15 µg/mL 6mp in
1.5 mL microcentrifuge tubes (Eppendorf, Hamburg, Germany). Cell viability was determined with
a hemocytometer (Sigma-Aldrich) under a stereo microscope. Since dead cells accumulated at the
bottom of the growth tube, we collected a 10 µL aliquot with swimming cells from the surface of
the growth medium. For counting, cells were immobilized by adding 0.5 µL of 37% formaldehyde
(Sigma-Aldrich).
2.2. Genomic Exclusion
To obtain homozygous homokaryons (mpr1-1/mpr1-1 [mpr1; 6mpr]), we crossed CU369 (mating-
type IV) and CU428.2 (mating-type VII) cells with A*V (mating-type V) cells. To make them competent
for mating, cells at mid-log phase (approximately 106/mL) were washed with 10 mM Tris-HCl (pH 7.4),
resuspended in 10 mM Tris-HCl (pH 7.4), and starved at 30 ◦C for approximately 18 h. To induce
mating, we mixed together equal numbers of cells of each mating type and incubated at 30 ◦C.
During the mating, one directional transfer of the migratory haploid gametic pronucleus occurred from
the wild-type parent to the star parent, followed by the blockage of mating without the production of
progeny nuclei. After refeeding the pairs with SPP, the haploid pronuclei underwent self-diploidization,
resulting in both parental cells having identical, functional, diploid whole genome-homozygous
MICs [1]. The parental cells retained their old MAC and hence their mating types. We isolated
cells of these two mating types and induced a second round of mating between them to produce
progeny. We selected progeny cells with MACs homozygous for 6mpr by cultivating in SPP containing
15 µg/mL 6mp.
2.3. Cloning and Sequencing of APRT1
APRT1 open reading frames (ORFs) were amplified from genomic DNA of the homozygous
homokaryons (mpr1-1/mpr1-1 [mpr1; 6mpr]), as well as from wild-type B2086.2 cells, with PrimeSTAR
Max DNA polymerase (Takara, Kusatsu, Japan) and the following primers: forward, GAGCTGAA
TGAATGAATGAATGAAT and reverse, CGTTTATTTATGACCTTTGACATCC. Amplified polymerase
chain reaction (PCR) products were integrated into the EcoRV site of the pBluescript SK(+) vector with
T4 DNA ligase (New England BioLabs, Ipswich, MA, USA). Cloned PCR products in the plasmids
were sequenced at LGC Genomics (Berlin, Germany) with the M13R primer, CAGGAAACAGCTA
TGAC. High-efficiency DH5 alpha-competent Escherichia coli cells (New England BioLabs) were used to
amplify all plasmids created in this study.
2.4. Construction of C-Terminal Epitope-Tagged Vectors
Plasmid pFZZ-NEO4 [25] contains FZZ (three tandem repeats of the FLAG epitope, a TEV
protease-sensitive site, and a protein A epitope) and a NEO4 drug-resistant marker [8]. To create
double-mutant strains (described in Section 3.4), we replaced the NEO4 cassette with a puromycin
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resistance marker (PAC) [11]. The NEO4 cassette was removed from the plasmid by digestion with
SalI and XmaI (New England BioLabs). pTOP2Gi-PAC [26] carries PAC under the control of the
MTT2 copper-inducible promoter [27] between SalI and XmaI sites. The MTT2-PAC cassette was
excised from pTOP2Gi-PAC and integrated into the SalI–ApaI sites of pFZZ-NEO4 with T4 DNA
ligase (New England BioLabs). The resulting plasmid (pFZZ-PAC) was used as a backbone plasmid
for further constructs. Approximately 1 kb of the ORF (5′) and untranslated region (UTR) (3′) of
the APRT1 genomic locus were amplified from the genomic DNA of the homozygous homokaryons
mpr1-1/mpr1-1 (mpr1; 6mpr) with PrimeSTAR Max DNA polymerase (TaKaRa) and the following
primers: ORF 5′ forward, ctaaagggaacaaaagctggagctcGAGCTGAATGAATGAATGAATGAAT; ORF
5′ reverse, accatcatgatctttgtaatcggatccTTCAATATGAAGATTAATAACCT; UTR 3′ forward, aatgcag
aagcttgtcgacctcgagGAATGAACAAGTTAGTTTGTTTTTG; and UTR 3′ reverse, ctcactatagggcgaatt
gggtaccCGTTTATTTATGACCTTTGACATCC. The nucleotides in lowercase correspond to consensus
sequences with the DNA ends of the backbone. The 5′ ORF sequence did not contain a stop
codon. The amplified PCR products were sequentially integrated into the SacI–BamHI sites and
XhoI–KpnI sites, respectively, of pFZZ-PAC with the NEBuilder HF DNA Assembly Kit (New England
BioLabs). The resulting plasmid (pD127-FZZ-PAC, Figure S1) was linearized with SacI and KpnI
(New England BioLabs) before biolistic transformation into T. thermophila [28]. The control plasmid,
which carried wild-type APRT1 instead of APRT1 from 6mpr cells, was also prepared. The PAC
cassette was activated by adding 630 µM CuSO4 to the transformed cells. Once puromycin-resistant
transformants were obtained, the concentration of CuSO4 was reduced to 20 µM for the efficient
induction of phenotypic assortment. Western blotting for tagged proteins was performed as described
previously [26]. Total protein (10 µg) extracted from growing cells in SPP medium was loaded into
each lane of a 4–15% precast polyacrylamide gel (Bio-Rad, Hercules, CA, USA), separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and transferred onto polyvinylidene
fluoride membrane (Bio-Rad). Anti-FLAG antibody (1:5000; Sigma-Aldrich) or anti-tubulin-alpha
antibody (1:10,000; NeoMarkers, Fremont, CA, USA) were used as primary antibodies.
2.5. Construction of Macronucleus (MAC) APRT1 Disruption Vector
Approximately 1 kb of sequences upstream (5′) and downstream (3′) of the macronuclear APRT1
genomic locus were amplified from B2086.2 genomic DNA with PrimeSTAR Max DNA polymerase
(Takara) and the following primers: 5′ forward, ctaaagggaacaaaagctggagctcGAGCTGAATGAATGAAT
GAATGAAT; 5′ reverse, aagatatcaagtcgacgcggccgccAATTTTATTACCCCACAAATCAATC; 3′ forward,
atgcagcccgggggatcagctcgagGGATCTTAAGGGCGAAGAAAGATTA; and 3′ reverse, ctcactatagggcga
attgggtaccCGTTTATTTATGACCTTTGACATCC. Amplified PCR products were sequentially
integrated into SacI–NotI sites and XhoI–KpnI sites of pNEO5 (a gift from Dr. Kazufumi Mochizuki,
Institute of Human Genetics, Montpellier, France) with the NEBuilder HF DNA Assembly Kit (New
England BioLabs). The resulting plasmid (p∆APRT1-NEO5, Figure S2) was linearized with SacI and
KpnI (New England BioLabs) before biolistic transformation into T. thermophila.
2.6. APRT1 RNA Interference (RNAi) Vector Construction and Gene Knockdown
T4 DNA ligase (New England BioLabs) was used to integrate double-stranded DNA (1146 bp)
that comprised two junk sequences separated by a 103-bp linker sequence (synthesized at Integrated
DNA Technologies, Coralville, IA, USA) into the PCR product amplified from pMTT1-D127N-NEO5
(Figure S3) with PrimeSTAR Max DNA polymerase (Takara) and the following primers: forward,
AAATAATAATACTAAACTTAAACAT and reverse, ACTAGTTGAGCGAACTGAATCGGTC, which
had been 5′ phosphorylated by T4 polynucleotide kinase (New England BioLabs). Figure S4 shows
the entire sequence of the resulting plasmid (pAkRNAi-NEO5). Target sequences used in hairpin
constructs (537 bp of the APRT1 ORF) were amplified from B2086.2 genomic DNA with PrimeSTAR
Max DNA polymerase (Takara) and the following primers: 5′ forward, taaacttaaacatcccggggg
atccGGATTACTAAAATTAAGAAATAGGT; 5′ reverse, ttgcatatccgttacttacggatccCATTCAATATGA
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AGATTAATAACCT; 3′ forward, taaaagaagaattcaaaggctgcagCATTCAATATGAAGATTAATAACCT;
and 3′ reverse, gctgaccgattcagttcgcctgcagGGATTACTAAAATTAAGAAATAGGT. Amplified forward
and reverse target fragments were cloned into the BamHI–BamHI and PstI–PstI I sites, respectively, of
pAkRNAi-NEO5 with the NEBuilder HF DNA Assembly Kit (New England BioLabs) to create the
hairpin cassette. The resulting plasmid (pAPRT1i-NEO5, Figure S5) was linearized with SacI and KpnI
(New England BioLabs) before biolistic transformation into T. thermophila. RNA interference (RNAi)
was induced in cells carrying the hairpin construct by adding 1 µg/mL CdCl2 (Sigma-Aldrich) to
promote double stranded RNA (dsRNA) expression from the MTT1 cadmium-inducible promoter [29].
2.7. Southern Blotting
Genomic DNA samples (5 µg) digested with BamHI and XhoI (New England BioLabs) were
electrophoresed through an 0.8% agarose gel and then transferred by capillary action onto a
Hybond-nylon membrane (GE Healthcare, Little Chalfont, UK) with 20× SSPE (3 M NaCl, 20 mM
EDTA, 154.8 mM Na2HPO4, and 45.2 mM H6NaO6P; pH 7.4). For the probe, a 579-bp PCR product
was amplified from B2086.2 wild-type genomic DNA with the following primers: forward, GAGCT
GAATGAATGAATGAATGAAT and reverse, AATTTTATTACCCCACAAATCAATC. The probe was
radioactively labeled by random priming with 32P-dATP (Hartmann Analytic, Braunschweig, Germany)
and hybridized to the DNA on the membrane. The signal was detected with an imaging plate (FUJIFILM
Corporation, Tokyo, Japan) and scanned with a Typhoon 9200 image analyzer (GE Healthcare). Band
intensity (a rough estimation of the degree of MAC assortment) was measured using ImageJ software.
2.8. Construction of EGFP-Tagged ATG8.2 Expression Vectors Based on pD127-FZZ-PAC
The ATG8.2 ORF was amplified from B2086.2 genomic DNA with PrimeSTAR Max DNA
polymerase (Takara) and the following primers: forward, ggatgaattatataagggatccATGGACGCTCAAA
ATTATAAACCC and reverse, cgattcagttcgctcaactagtAATTGATCCAAATACTTCTTGATCAGAG.
The amplified PCR product was integrated into the BamHI–SpeI sites of pBNMB1-EGFP
with the NEBuilder HF DNA Assembly Kit (New England BioLabs). The resulting plasmid
(pEGFP-ATG8.2-NEO5) contained a polyadenylation (polyA) signal followed by the MTT1 promoter,
the EGFP cassette, the ATG8.2 ORF, and the 3′ UTR of BTU1. These consecutive components were
amplified as a single fragment with the following primers: forward, tattaatcttcatattgaaggatccTG
AGATCCTTAAATTAAAAATTCAATAT and reverse, aacttgttcattcctcgaggtcgacAAGATGTGGCT
ATTGATGGGCATAA. The amplified fragment was integrated into the BamHI–SalI sites of
pD127-FZZ-PAC with the NEBuilder HF DNA Assembly Kit (New England BioLabs). The resulting
plasmid (pD127-EGFP-ATG8.2, Figure S6) was linearized with SacI and KpnI (New England BioLabs)
before biolistic transformation into T. thermophila.
2.9. Construction of EGFP-Tagged ATG8.2 Expression Vectors Based on p∆APRT1-NEO5
A DNA fragment containing the MTT1 promoter followed by the EGFP cassette, the
ATG8.2 ORF, and the 3′ UTR of the BTU1 gene was amplified from pEGFP-ATG8.2-NEO5 with
PrimeSTAR Max DNA polymerase (Takara) and the following primers: forward, ataaacaaaatccag
atcccccgggGGATCAGACAATTTATTTCTAAAAA and reverse, aacttgttcattcctcgaggtcgacAAGAT
GTGGCTATTGATGGGCATAA. The amplified fragment was integrated into the XmaI–SalI sites
of p∆APRT1-NEO5 with the NEBuilder HF DNA Assembly Kit (New England BioLabs). The resulting
plasmid (pEGFP-ATG8.2 APRT1 locus, Figure S7) was linearized with SacI and KpnI (New England
BioLabs) before biolistic transformation into T. thermophila.
2.10. Construction of EGFP-Tagged TOP2S Expression Vectors Based on pAPRT1i-NEO5
A DNA fragment containing the NEO5 cassette followed by the MTT1 promoter, the hairpin
RNAi region, and the 3′ portion of the BTU1 genomic locus was excised from pAPRT1i-NEO5 with
SalI and ApaI (New England BioLabs). It was integrated into the SalI–ApaI sites of pTOP2S-EGFP-
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NEO4 [26] with T4 DNA ligase (New England BioLabs). The resulting plasmid (pTOP2S-EGFP-
NEO5-APRT1i, Figure S8) was linearized with SacI and KpnI (New England BioLabs) before
biolistic transformation into T. thermophila. The double mutant carried both TOP2S-EGFP and
HHT-mCherry, as confirmed by PCR with the diagnostic primers TOPS-EGFP forward, ACGCTAAG
GAGCAGACCTCG; TOPS-EGFP reverse, ACTAGTCTTATATAATTCATCCATA; HHT-mCherry
forward, ATGGCTAGAACTAAATAAACTGCTA; and HHT-mCherry reverse, GAATATCCCATGCG
AAAGGTAAAGG.
3. Results and Discussion
3.1. Mutation in APRT1 of 6mpr Strains
APRTase plays a critical role in adenine salvage in most living organisms [23].
The phosphoribosyltransferase (PRTase) protein family catalyzes Mg2+-dependent replacement
of the 1-pyroposphate group from PRPP with a purine base to form the corresponding purine
nucleoside 5′-monophosphate. In many organisms, purine nucleotides, including AMP, can be
generated via a de novo synthetic pathway; in addition, several purine salvage pathways incorporate
preformed purine bases and nucleosides into the purine nucleotide pool.
APRTase has been implicated in resistance to 6mp in N. crassa [22] and the archaeon S. islandicus [24].
A BLASTP search of the T. thermophila genome database (http://www.ciliate.org/) revealed that
TTHERM_00011180 (APRT1) alone encodes a protein similar to the eukaryotic N. crassa APRTase
(GenBank: EAA34491.3). This potential APRTase contains a PRTase-type I domain, a characteristic of
PRPP-binding proteins, and putative active sites important for enzyme function (Figure 3). Similarly,
S. islandicus APRTase (ACR40792.1) shares the PRTase-type I domain, as well as some of the putative
active sites, with eukaryotic APRTases (Figure 3). However, the entire sequence of S. islandicus
APRTase is similar to prokaryotic PRTases with specificities for hypoxanthine, guanine, xanthine,
and/or adenine, which are not conserved in T. thermophila or N. crassa (http://fungi.ensembl.org/
Neurospora_crassa/Info/Index), implying that the eukaryotic and prokaryotic APRTases work as
isozymes. Indeed, a gene (TK0664) encoding hypoxanthine–guanine PRTase has been used as a 6mp
counterselective marker in the archaeon Thermococcus barophilus [30].
Figure 3. Multiple-sequence alignment of the entire amino acid sequences of Sulfolobus islandicus,
Neurospora crassa, and T. thermophila adenine phosphoribosyltransferases (APRTases). Purple boxes
indicate the phosphoribosyltransferase (PRTase)-type I domain. Amino acids in blue and red correspond
to putative active sites important for prokaryotic and eukaryotic APRTase functions, respectively.
Asterisks indicate identical amino acids. Colons and semicolons indicate amino acid similarity.
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T. thermophila strains CU369 and CU428.2 are both functional homozygous heterokaryons
(mpr1-1/mpr1-1 [6mps]) derived from the natural isolate B strain [31]; both carry the allele for 6mp-
resistance that was induced by MNNG-treatment of mating cells [19]. To search for mutation(s) at the
APRT1 genomic locus, we created homozygous homokaryons (mpr1-1/mpr1-1 [6mpr]) by mating CU369
and CU428.2 to star strain A*V for two rounds of genomic exclusion, an aberrant form of mating that
creates whole-genome homozygotes (Figure 4A). We cloned the APRT1 ORF and found a mutation at
position 379, a change from guanine to adenine (Figure 4B). This mutation causes an amino acid change
at position 127 from aspartic acid to asparagine (Figure 4C), which removes a conserved putative active
site found in both the prokaryotic and eukaryotic enzymes (Figure 3). This result suggests that the
mutation in APRT1 is responsible for 6mp resistance.
Figure 4. Cont.
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Figure 4. Identification of a mutation in APRT1. (A) Diagram illustrating the process of genomic
exclusion to generate homozygous homokaryons. Star strains possess a dysfunctional MIC, represented
by a cross. Black and red arrows correspond to the first and second rounds of mating, respectively.
Black and white nuclei indicate 6mp-resistant and -sensitive genotypes, respectively. † denotes nuclei
destined to degrade, such as unselected haploid MICs and old parental MACs. (B) Multiple-sequence
alignment of the sequenced APRT1 genes, including B2086.2 and homozygous homokaryons derived
from CU369 and CU428.2. SB210 corresponds to the sequence obtained from the Tetrahymena genome
database. Asterisks indicate identical nucleotides. Nucleotides in red at position 379 denote a common
mutation found in this study. (C) Translation of the sequenced APRT1 genes. Asterisks indicate
identical amino acids. The amino acid change caused by the mutation at position 127 is indicated
in red.
3.2. Expression of D127N from APRT1 Genomic Locus Confers 6mp Resistance
Resistance to 6mp in N. crassa [22] and the archaeon S. islandicus [24] has been suggested to result
from inactivation of APRTase. Thus, we speculated as to whether mutation D127N affects T. thermophila
APRTase activity. To test if D127N expression makes cells resistant to 6mp, we replaced wild-type MAC
APRT1 with mutated APRT1 by integrating a C-terminal FZZ-tagged D127N gene-fusion product
(from pD127-FZZ-PAC) into the macronuclear APRT1 locus of B2086.2 cells (Figure 5A). As a control, a
C-terminal FZZ-tagged wild-type APRT1 gene-fusion product was also integrated into B2086.2 cells.
Transformants were maintained in the presence of the selective agent, 2 mg/mL puromycin [11], for
2 months.
Southern blotting revealed that the original APRT1 copies in the MAC had been completely
replaced by the FZZ constructs (Figure 5B). Western blotting demonstrated that both wild-type and
mutant transformants expressed FZZ-tagged proteins under the control of the endogenous APRT1
promoter (Figure 5C).
To measure growth rate, we exposed both wild-type and mutant transformants to 15 µg/mL
6mp, which kills sensitive cells within 72 h [20,32]. B2086.2 (6mps) and heterozygous progeny cells of
a B2086.2 and CU428.2 mating (mpr1-1/MPR1-1 [6mpr]) were used as 6mp-sensitive and -resistant
control cells, respectively. Wild-type APRTase-FZZ-expressing cells were sensitive to 6mp, whereas
D127N-FZZ-expressing cells grew similarly to 6mpr control cells and had reached >106 cells/mL by
72 h (Figure 3D). These results suggest that the D127N mutant protein has little to no enzyme activity,
thus preventing the incorporation of a lethal dose of 6mp. Indeed, ectopic expression of D127N from
a non-APRT1 locus in B2086.2 cells did not confer 6mp resistance (Figure S3), suggesting that the
resistance conferred by D127N is dependent upon wild-type APRTase dosage rather than upon the
ratio of wild-type to mutant APRTase expression.
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Figure 5. Effect on cell sensitivity to 6mp of replacing wild-type APRT1 with the mutant gene. (A) A
schematic showing the APRT1 genomic locus (upper), the plasmid vector pD127N-FZZ-PAC, with
the mutant gene, FZZ tag containing polyA signal, and puromycin resistant cassette (PAC) (middle),
and after homologous recombination (lower). Control plasmid carries wild-type APRT1 instead of
the mutated version. (B) Southern blot analysis of XhoI- and BamHI-digested genomic DNA from
wild-type cells and FZZ-tagged APRTase-expressing transformants. The molecular weight of signals
against the probe corresponds to the prediction in (A). (C) Western blot analysis of FZZ-tagged
APRTases. FZZ tag and APRTase were 17 kDa and 20 kDa, respectively, resulting in a single 37 kDa
band. Tubulin-alpha was the loading control. (D) Cell growth curves in the presence of 15 µg/mL 6mp.
Points and attached bars correspond to mean measurements from three identical experiments and their
standard deviations, respectively. Cells sensitive to 6mp all died by 72 h.
3.3. Partial Loss of MAC APRT1 Copies is Sufficient to Confer 6mp Resistance
Resistance to 6mp results from knockout of an APRT ortholog [24] in S. islandicus and complete
replacement of wild-type APRT1 with the D127N allele in T. thermophila (Figure 5D). However, ectopic
overexpression of D127N did not cause resistance (Figure S3). These observations suggest that reduced
numbers of wild-type APRT1 copies, rather than D127N expression, are critical to 6mp resistance.
To investigate this possibility, we integrated a somatic knockout construct (p∆APRT1-NEO5) carrying
the neomycin resistance marker NEO5 into the MAC APRT1 locus of wild-type B2086.2 cells (Figure 6A).
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After an initial 3-day drug selection with 100 µg/mL paromomycin (a neomycin derivative), the
resulting transformant cells had not completed phenotypic assortment. Southern blotting revealed
partial somatic APRT1 knockout of approximately 30% of the copies (Figure 6B).
Figure 6. Effect of partial APRT1 knockout on cell sensitivity to 6mp. (A) A schematic showing the
APRT1 genomic locus (upper), the plasmid vector p∆APRT1-NEO5, with paromomycin resistance
cassette (NEO5) (middle), and after homologous recombination (lower). (B) Southern blot analysis
of XhoI- and BamHI-digested genomic DNA from wild-type cells and partial APRT1 knockout cells.
Molecular weight of signals against the probe corresponds to the prediction in (A). (C) Cell growth
curves in the presence of 15 µg/mL 6mp. Points and attached bars correspond to mean measurements
from three identical experiments and their standard deviations, respectively. Cells sensitive to 6mp
all died by 72 h. (D) Southern blot analysis of XhoI- and BamHI-digested genomic DNA from partial
APRT1 knockout cells before and after measurement of cell growth rates in 6mp. (E) Southern blot
analysis of XhoI-and BamHI-digested genomic DNA from partial APRT1 knockout cells before and
after the induction of phenotypic assortment with 5 mg/mL paromomycin for 2 months. Molecular
weight of signals against the probe corresponds to that predicted in the schematic in (A).
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When exposed to 15 µg/mL 6mp, the partial APRT1 knockout cells grew similarly to 6mpr control
cells, reaching >106 cells/mL at 72 h (Figure 6C). Southern blotting after 72 h showed complete loss of
wild-type APRT1 copies without adding paromomycin (Figure 6D). This is evidence of exceptionally
quick phenotypic assortment compared to paromomycin selection: Even after 2 months of cultivation
in 5 mg/mL paromomycin, assortment remained unfinished, with a ratio between the two APRT1
alleles of approximately 1:1 (Figure 6E). This suggests that in T. thermophila, 6mp is a stronger negative
selective agent than paromomycin.
These results support the hypothesis that attenuated APRTase activity, due to the D127N mutation,
is responsible for 6mp resistance. The initial partial loss of APRT1 copies may confer limited
resistance to 6mp and promote quick phenotypic assortment to allow survival under continuous
selective pressure.
3.4. RNAi Against APRT1 Enables Survival in the Presence of 6mp
To confirm that 6mp resistance in T. thermophila was due to reduced APRTase activity, we
integrated a short hairpin RNAi construct (pAPRT1i-NEO5) controlled by the MTT1 promoter into
the MAC BTU1 locus of B2086.2 cells (Figure 7A). The same construct was also introduced into the
wild-type APRTase-FZZ-expressing strain (Figure 5C). Western blotting showed that APRTase-FZZ
expression was largely abolished after cadmium induction of RNAi for 6 h (Figure 7B), which
demonstrates that the RNAi construct was effective. The transformant cells became resistant to
15 µg/mL 6mp upon activation of RNA interference by 1 µg/mL CdCl2 (Figure 7C). This confirms
that suppression of APRTase expression was responsible for the 6mp resistance.
In S. islandicus, addition of either AMP or guanosine monophosphate (GMP), both of which are
non-essential in the wild-type strain, is required to maintain robust growth of the APRT knockout
strain [24]. The utilization of GMP is probably due to the interconversion between GMP and
AMP in purine metabolism, which has been observed in Salmonella typhimurium [33]. In the ciliate
T. thermophila, we found that neither knockout nor knockdown of APRT1 affected robust cell growth
(Figures 6C and 7C), which indicates that, unlike in prokaryotes and Giardia lamblia, in which
adenine salvage provides the sole mechanism to produce AMP [34], APRTase is not required for
cell growth. This independence from adenine salvage is similar to that seen in mammals, in which
APRTase-dependent salvage is redundant with de novo adenosine synthesis (although it becomes more
important during periods of vigorous cell growth, such as embryogenesis and tumor growth) [35].
Purine salvage appears to be redundant in T. thermophila, and sufficient AMP is most likely created
through de novo synthesis.
Figure 7. Cont.
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Figure 7. Effect of APRT1 interference RNA (RNAi) on cell sensitivity to 6mp. (A) A schematic showing
the BTU1 genomic locus (upper), the plasmid vector pAPRT1i-NEO5, with paromomycin resistance
cassette (NEO5), cadmium-inducible MTT1 promoter, and hairpin RNAi cassette containing BTU1’s
polyA signal (lower). (B) Western blot analysis of FZZ-tagged APRTase in RNAi non-induced and
induced cells (exposed to 1 µg/mL CdCl2 in super proteose peptone (SPP) medium for 6 h or 24 h).
Tubulin-alpha was the loading control. (C) Cell growth curves in 15 µg/mL 6mp. Points and attached
bars correspond to the mean of three identical measurements and standard deviations. Cells sensitive
to 6mp all died by 72 h.
3.5. Potential Utility of APRT1 as a New Selection Marker
Our identification of APRT1 as the gene responsible for 6mp resistance allowed us to add 6mp
resistance to the set of available selectable drug resistance markers in T. thermophila. To evaluate
whether selection of 6mp resistance could be used practically, we created three types of vectors:
pD127N-EGFP-ATG8.2, pEGFP-ATG8.2 APRT1 locus, and pTOP2S-EGFP-NEO5-APRT1i (Figures S6–S8;
described in Materials and Methods Sections 2.8–2.10). pD127N-EGFP-ATG8.2 and pEGFP-ATG8.2
APRT1 locus (APRT1 locus-based systems) were designed to select for 6mpr transformants by
replacing the wild-type ARPT1 copies in the MAC with either a non-functional (Figure 8A) or a
deleted gene (Figure 8B), respectively. These constructs replace the functional APRT1 gene with
EGFP-ATG8.2, a fluorescently labeled protein that is targeted to autophagosomes in T. thermophila [36].
pTOP2S-EGFP-NEO5-APRT1i (RNAi-based system) was designed to suppress APRTase expression
(resulting in 6mp resistance) upon induction of RNAi by cadmium treatment; once transformants are
selected, transgenes can be maintained at the target locus through paromomycin resistance (Figure 8C).
In strains that are already resistant to paromomycin, this approach could be used to select for secondary
transformants. Withdrawal of cadmium after selection loading to inactivation of RNAi could minimize
non-specific and off-target effects of the RNAi [37]. To test whether such double transformants
could be generated, we biolistically bombarded each vector into a 6mp-sensitive (MPR1-1/MPR1-1)
histone H3 (HHT)-mCherry-expressing strain in which the MAC carries a NEO5 cassette following the
mCherry cassette.
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Figure 8. APRT1 as a new selection marker. (A) A schematic diagram showing the APRT1 genomic
locus (upper) and the plasmid vector pD127N-EGFP-ATG8.2, with the mutated gene containing polyA
signal and EGFP-tagged ATG8.2 overexpression cassette (lower). (B) A schematic diagram showing the
APRT1 genomic locus (upper) and the plasmid vector pEGFP-ATG8.2 APRT1 locus, with EGFP-tagged
ATG8.2 overexpression cassette (lower). These constructs replace the functional APRT1 gene with
EGFP-ATG8.2 by homologous recombination. (C) A schematic diagram showing the TOP2S genomic
locus (upper) and the plasmid vector pTOP2S-EGFP-NEO5-APRT1i, with EGFP tag containing polyA
signal, paromomycin resistance cassette (NEO5), cadmium-inducible MTT1 promoter, and hairpin
RNAi cassette containing polyA signal (lower) with crossover sites for homologous recombination
indicated. Selection is performed in the presence of cadmium. Once 6mp-resistant transformants
are selected, the production of double stranded RNAs (dsRNAs) is inactivated by withdrawal of
cadmium to minimize non-specific and off-target effects of the RNAi. The NEO5 cassette maintains
the construct by culturing the transformants with paromomycin, ultimately leading to homozygosity
of the MAC. These plasmids were biolistically bombarded into an HHT-mCherry-expressing strain
(MPR1-1/MPR1-1, 6mps).
After biolistic bombardment, the cells were incubated in SPP at 30 ◦C for 24 h followed by exposure
to various concentrations of 6mp (0.47, 0.95, 1.9, 3.8, 7.5, and 15 µg/mL). For the RNAi-based system,
we added 1 µg/mL CdCl2 to induce the production of short hairpin RNA against APRT1. Aliquots were
then transferred to 96-well plates, which were incubated at 30 ◦C for 3 days. We found that >1.9 µg/mL
concentrations of 6mp killed all cells within 3 days, whereas lower concentrations hardly affected cells.
However, in 1.9 µg/mL 6mp a small fraction of cells in every well survived, and we observed slow
propagation in some of these wells, probably due to the depletion of 6mp. We transferred 50-µL aliquots
from these wells to new 96-well plates with 200 µL/well SPP plus 1.9 µg/mL 6mp. After incubation at
30 ◦C for 3 days, a single well from the RNAi-based system contained rapidly proliferating putative
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transformed cells. No such transformants were seen for the other APRT1 locus-based systems, even
after incubating them for another 5 days. Diagnostic PCR (Figure 9A,B) and fluorescence microscopic
observation of live cells (Figure 9C) verified that the RNAi-based 6mpr transformants were double
mutant transformants. Due to the NEO5 cassettes present in both the HHT-mCherry and pTOP2S-EGFP
constructs (Figure 9A), the double transformants could be stably maintained even after cessation
of RNAi by culturing the cells with paromomycin. We repeated the screening in triplicate, and the
RNAi-based system consistently yielded double mutant transformants (Table 1), although the efficiency
was not as high as with paromomycin- and puromycin-resistant systems [8,11]. We believe, however,
that the system can be optimized by manipulating 6mp concentrations.
Figure 9. APRT1 RNAi cassette acts as a 6mp selection marker. (A) Schematic representation of a
double-mutant strain made with pTOP2S-EGFP-NEO5-APRT1i and confirmed by diagnostic PCR. PCR
primer sets indicated by white triangles. (B) Fragments from TOP2S-EGFP and HHT-mCherry genomic
loci were amplified from DNA isolated from 6mp-resistant cells, while only the fragment from the
HHT-mCherry genomic locus could be amplified from the original HHT-mCherry-expressing cells.
(C) Only the double mutant strain expressed TOPS-EGFP, which was localized exclusively to the MAC,
and HHT-mCherry, which was localized to both the MAC and the MIC. Numerous food vacuoles
dispersed in the cytoplasm had green autofluorescence. Scale bar denotes 10 µm.
Table 1. Number of wells with 6mp-resistant cells.
Transformation Plasmids Exp. 1 Exp. 2 Exp. 3 Exp. 4
pD127N-EGFP-ATG8.2 0/96 0/96 0/96 0/96
pEGFP-ATG8.2 APRT1 locus 0/96 0/96 0/96 0/96
pTOP2S-EGFP-NEO5-APRT1i 1/96 0/96 1/96 1/96
In T. thermophila, paromomycin is the most popular selection drug. It is used not only to select
for NEO-based constructs, but also to select for autonomously replicating vectors carrying a mutation
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in the 17S rRNA gene [38], which makes cells resistant to paromomycin [39]. The APTR1-RNAi-
NEO5 hybrid system could have useful applications in creating double mutant transformants in
paromomycin-resistant strains for the following reasons: (1) when cadmium is present, it provides a
selection marker for 6mp, and (2) paromomycin alone maintains the two different transgenes after
screening. Unfortunately, we found that the APRT1 locus-based systems failed to give us transformants,
no doubt because the acquisition of 6mp resistance requires a substantial reduction in the number of
wild-type APRT1 copies. The APRT1 locus-based system could serve as a markerless transformation
tool for gemline knockouts [28]. Transformation during meiotic prophase results in progeny MACs
that have lost 50% of their wild-type APRT1 copies, enough to allow them to become 6mp resistant (as
heterozygotes are resistant). In this scenario, homozygous homokaryons (MPR1-1/MPR1-1, 6mps) are
a prerequisite for both parents.
4. Conclusions
Classical 6mp resistance in T. thermophila is due to inactivation of the APRTase by a mutation in
the MIC APRT1 gene. This knowledge may be used to create novel tools for genetic manipulation of
Tetrahymena.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4425/9/4/179/s1,
Figure S1: Map of the endogenous APRTase expression plasmid pD127N-FZZ-PAC, with a puromycin resistance
cassette (PAC), FZZ tag containing polyA signal, mutated APRT1 ORF plus 5′ UTR, and 3′ UTR of APRT1.,
Figure S2: Map of the MAC APRT1 knockout plasmid p∆APRT1-NEO5, with paromomycin-resistance cassette
(NEO5) and 5′ and 3′ flanking sequences of APRT1., Figure S3: Effect of overexpression of mutant APRTase on
cell sensitivity to 6mp., Figure S4: Map of the RNAi backbone plasmid pAkRNAi-NEO5, with paromomycin
resistance cassette (NEO5), MTT1 promoter, junk DNA sequences separated by a linker sequence, and 5′ and 3′
UTRs of BTU1., Figure S5: Map of the APRT1 knockdown plasmid pAPRT1i-NEO5, with paromomycin resistance
cassette (NEO5), cadmium-inducible MTT1 promoter, hairpin RNAi cassette, and 5′ and 3′ UTRs of the MAC
BTU1., Figure S6: Map of trial plasmid pD127N-EGFP-ATG8.2., Figure S7: Map of trial plasmid pEGFP-ATG8.2
APRT1 locus., Figure S8: Map of trial plasmid pTOP2S-EGFP-NEO5-APRT1i.
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